Within weeks of becoming chief executive of GSK Plc, Luke Miels took responsibility for a $2.2 billion deal to acquire RAPT Therapeutics, a US company with a late stage product for food allergies. The acquisition will give GSK a monoclonal antibody that is being developed as a prophylactic with a dosing schedule potentially more attractive than a product marketed by Roche.
AstraZeneca Plc is to expand its drug manufacturing and research and development presence in China with an investment of $15 billion through 2030. China is already the company’s second largest market after the US, as well as a significant source of medical research and business collaborations. The new investment will build on this foundation. AstraZeneca announced the plan on 29 January, concurrent with a visit by UK Prime Minister Keir Starmer to China to strengthen economic ties between the two countries.
GSK Plc has reach an agreement to acquire US-based RAPT Therapeutics Inc for $2.2 billion, strengthening its position in the field of medicines for inflammatory and immunologic diseases. The US company’s lead product, ozureprubart, is a monoclonal antibody that is being developed as a prophylactic against food allergens. It targets immunoglobulin E (IgE) which is the mode of action of at least one other approved biologic. Other treatments include allergen-specific immunotherapies. The standard of care is avoidance of allergens.
Oncology Review
Oncology drug approvals rise, led by China
Public Policy
A plan to empower the EU single market
Advanced Therapies
A business model for cell and gene therapies
Regulation and Policy
Contours of the new EU pharma
legislation are visible
Stock Market Performance
The focus is now on politics
Commentary
Reflections on JP Morgan meeting
A business model for cell and gene therapies
(119.24 KB)
